Clarivate Epidemiology’s coverage of thyroid cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed incidence and diagnosed prevalence of thyroid cancer for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the remaining countries covered in this report. In addition to forecasting the diagnosed incident and prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy in the major mature pharmaceutical markets.
Clarivate Epidemiology’s thyroid cancer forecast will answer the following questions:
Of all people diagnosed with thyroid cancer in the major mature pharmaceutical markets, how many are drug-treated?
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of thyroid cancer over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts 47 thyroid cancer patient populations, including the following:
Diagnosed incident cases of papillary thyroid cancer.
Diagnosed incident cases of follicular thyroid cancer.
Diagnosed incident cases of medullary thyroid cancer.
Diagnosed incident cases of anaplastic thyroid cancer.
Diagnosed prevalent cases of papillary thyroid cancer.
Diagnosed prevalent cases of follicular thyroid cancer.
Diagnosed prevalent cases of medullary thyroid cancer.
Diagnosed prevalent cases of anaplastic thyroid cancer.
Diagnosed incident cases of metastatic recurrent differentiated thyroid cancer refractory to radioactive iodine.
Literature review (studies included in/excluded from the analyses of thyroid cancer)
Diagnosed incident cases
Stage distribution of thyroid cancer
Recurrent incident cases of thyroid cancer
Diagnosed prevalent cases
Drug-treatable populations
Drug-treated population
Risk/protective factors applied to disease forecast models
Reference materials
Bibliography
Glossary
Abbreviation table
Yueyao (Alex) Li
Yueyao (Alex) Li, M.D., Ph.D., M.S.P.H.,is an associate epidemiologist at Clarivate. Previously, she was a postdoctoral researcher at Brown University, where she worked on projects relating to skin cancer and chronic skin conditions. Dr. Li holds a medical degree specializing in general surgery from China Medical University. She also holds a Ph.D. in epidemiology from Indiana University and a master’s degree in public health from the University of South Carolina.
Sunali D. Goonesekera, S.M.
Sunali D. Goonesekera, S.M., Senior Manager, Epidemiology. Prior to joining Clarivate, Ms. Goonesekera conducted epidemiological research on racial/ethnic disparities in metabolic diseases at the New England Research Institute and lead-authored two manuscripts. She has contributed to multiple publications in peer-reviewed journals in epidemiology and the biological sciences. She holds a master’s degree in epidemiology from the Harvard School of Public Health and a B.A. in biology (Honors) from Dartmouth College.
